ERBB2 and gastric cancer: FS-1502 showed potent antitumor activity in xenograft models bearing HER2-positive breast cancer or gastric cancer tumors, and it could also inhibit the growth of HER2-low tumors that were resistant to T-DM1 in xenograft models24.